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Notes from the Field
Use of Asynchronous Video Directly Observed 
Therapy for Treatment of Tuberculosis and Latent 
Tuberculosis Infection in a Long-Term–Care 
Facility — Puerto Rico, 2016–2017
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To treat a cluster of tuberculosis (TB) transmission cases 
in a long-term care facility for cognitively impaired adults 
located in Puerto Rico (facility A), the Puerto Rico TB Control 
Program used a novel video directly observed therapy (VDOT) 
application. In 2016, active TB disease was diagnosed in 11 
residents and latent TB infection (LTBI) was diagnosed in 
six residents of facility A. Asynchronous VDOT was used to 
monitor treatment for these 17 residents. One of the patients 
with active TB disease had received a diagnosis of LTBI during 
an investigation at facility A during 2011–2012.
During 2010–2012, seven residents of facility A received 
a diagnosis of active TB disease; four of these diagnoses 
were culture-confirmed, with isolates that had the same rare 
genotype (1). Drug susceptibility testing indicated sensitiv-
ity to the standard first-line regimen of rifampin, isoniazid, 
pyrazinamide, and ethambutol (RIPE). Three of the seven 
TB patients died before starting treatment; the other four 
were prescribed the RIPE regimen under the supervision of 
personnel from facility A. Two of the four patients who report-
edly completed RIPE treatment in 2012 died in 2016 from 
unrecognized TB-related conditions; both patients were room-
mates of the 2016 index case patient. For these two patients, 
evidence of TB discovered during a postmortem medical record 
review included ineffective antibiotic treatments for putative 
community-acquired pneumonia and bronchitis and signs 
of wasting, which were corroborated by interviews with staff 
members and treating physician. No patients at facility A tested 
positive for human immunodeficiency virus infection in 2012 
or 2016. The contact investigation performed in 2011–2012 
identified LTBI in 26 residents and seven nonresidents. All 
contacts with LTBI were reported by facility staff members as 
having completed treatment with 4 months of daily rifampin 
(4R), one of a few standard LTBI regimens, in 2012.
On June 20, 2016, a resident of facility A, who was a contact 
from the 2011–2012 investigation and whose facility records 
indicated prior treatment for LTBI with 4R, was identified as 
having advanced cavitary TB disease; the genotype and drug 
susceptibility testing of this patient’s isolate matched that 
of the original cases. This resident began treatment with a 
6-month course of RIPE; ethambutol was discontinued after 
drug sensitivities were confirmed. Among 38 residents and 15 
staff members, 10 additional cases of active TB disease were 
diagnosed among residents; these patients were prescribed 
rifampin, isoniazid, and pyrazinamide (without ethambutol). 
Six other residents with diagnosed LTBI were prescribed 
4R treatment. Because of staffing shortages, Puerto Rico 
Department of Health (PRDH) TB field personnel were not 
available to administer daily directly observed therapy (DOT) 
at facility A and facility A did not have the personnel needed 
to provide daily patient transport to the PRDH clinic.
VDOT uses video and computer equipment that allows 
public health officials to observe patients taking medications 
for TB, and it has been successfully used to ensure proper 
completion of TB treatment (2–5). A standard live VDOT 
protocol (e.g., using FaceTime) (4) was attempted at facility A 
but was not sustainable because cell phones or Internet connec-
tivity were not consistently available. An asynchronous VDOT 
protocol that did not require real-time Internet connection or 
a cellular plan, complied with the Health Insurance Portability 
and Accountability Act, and provided a Spanish external-facing 
application*,† was implemented to ensure proper treatment 
for TB and LTBI patients. Use of this asynchronous system 
avoided audio/visual interruption related to poor connectivity, 
which can be problematic in standard live VDOT applications 
(4), by capturing and storing videos of patients as they swal-
lowed their TB medications, and automatically uploading the 
videos after Internet connection became available. Videos were 
viewed by PRDH staff members at 2–10 times the speed at 
which they were recorded. In addition to the clinic-to-facility 
commute, which would have taken 1.5 hours per day, DOT 
for the 17 severely cognitively challenged men would have 
required an additional 1.5 hours per day of observation. Use of 
asynchronous VDOT saved PRDH approximately 240 hours 
in DOT-related activities, equivalent to 25% of the workload 
for a full-time epidemiology technician/case manager over 
6 months of treatment.
As of July 12, 2017, all 11 patients with active TB disease 
and all six with LTBI had completed treatment with recom-
mended ≥80% compliance (percentage of scheduled doses 
actually taken) (Table) (6). Active TB disease treatment rates 
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TABLE. Active tuberculosis (TB) disease and latent tuberculosis 
infection (LTBI) patient compliance with daily directly observed 











Active TB cases  (n = 11): completion of 6-month treatment for active TB 
disease with RIF, INH, and PZA*
11 94 132 140 28
4 93 124 133 37¶
5 91 128 140 28
7 90 126 140 28
8 92 133 145 29
9 96 149 155 31
10 93 121 130 26
12 90 117 130 26
13 91 127 140 28
14 93 125 135 27
15 93 130 140 28
All 92 1,412 1,528 —
LTBI patients (n = 6): completion of 4-month treatment for LTBI with RIF
16 86 94 110 22
17 88 96 110 22
18 88 97 110 22
19 85 93 110 22
20 87 95 110 22
21 91 100 110 22
All 87 575 660 —
Abbreviations: INH = Isoniazid; LTBI = latent TB infection; PZA = Pyrazinamide; 
RIV = Rifampin.
* Percentage of recommended doses taken.
† CDC recommends completion of 130-dose treatment during a 5 day/week 
regimen for active TB disease and compliance is recommended to be at least 
80%. Doses taken were counted only during weeks in which ≥4 doses occurred 
(80% compliance). For LTBI, CDC recommends completion of 120-dose 
Rifampin treatment during a 7 day/week regimen. Duration of treatment was 
extended from 16 to 22 weeks to accommodate 5 day/week dosing and achieve 
80% compliance. https://www.cdc.gov/tb/publications/ltbi/treatment.
htm#treatmentRegimens
§ Including the index case, patient 11, active TB patients began treatment over 
a range of several weeks as clinical signs and symptoms of disease were 
identified. Group visits to the TB clinic occurred simultaneously for all patients.
¶ Patient 4 received a modified treatment plan for active disease during phase 1. 
Standard doses were taken 3 days/week instead of 5 days/week because of 
interactions with other medications.
used asynchronous VDOT to observe directly any complex 
patients on multiple hepatotoxic drugs for side effects that 
could interfere with treatment compliance and to verify a 
daily measurement of treatment completion. VDOT has been 
demonstrated to be cost-effective in multiple settings (5). 
CDC has developed an eDOT toolkit (https://www.cdc.gov/
tb/publications/guidestoolkits/tbedottoolkit.htm) to facilitate 
adoption of these practices.
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treating 5 days per week; LTBI treatment, however, is normally 
7 days per week and, in this case, was extended by 1 month 
to achieve ≥80% compliance. All patients with active TB 
disease have shown clinical signs of improvement. In addition 
to using daily symptom queries attached to the videos and 
telephonic communication as needed, the medical director 
Morbidity and Mortality Weekly Report 
1388 MMWR / December 22, 2017 / Vol. 66 / No. 50 US Department of Health and Human Services/Centers for Disease Control and Prevention
Erratum
Vol. 66, No. 32
In the report “Progress Toward Poliomyelitis Eradication — 
Afghanistan, January 2016–June 2017,” on page 857, the last 
sentence of the last paragraph should have read “Detection 
of orphan viruses, which are ≥1.5% divergent from the most 
closely related isolate, indicating extended undetected circula-
tion of poliovirus, along with continued close genetic linkages 
with Pakistan viruses, highlight the need for Afghanistan and 
Pakistan to continue to prioritize coordination to improve 
surveillance, and to track and vaccinate their mobile popula-
tions, thereby stopping the ongoing cross border transmission 
and reducing the risk for poliovirus circulation in hard-to-reach 
areas of Afghanistan.”
